 | |
| Clinical data | |
|---|---|
| Trade names | Lytgobi |
| Other names | TAS-120 |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| License data | |
| Routes of administration | By mouth |
| Drug class | Antineoplastic |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| PDB ligand | |
| Chemical and physical data | |
| Formula | C22H22N6O3 |
| Molar mass | 418.457 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Futibatinib, sold under the brand nameLytgobi, is ananti-cancer medication used for the treatment ofcholangiocarcinoma (bile duct cancer).[1][3] It is a kinase inhibitor.[1][6] It is takenby mouth.[1]
Futibatinib was approved for medical use in the United States in September 2022,[1][3][7][2] in Japan in June 2023[8][9] and in the European Union in July 2023.[4][10]
Futibatinib isindicated for the treatment of adults with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.[1][3][2][11]
On 26 April 2023, theCommittee for Medicinal Products for Human Use (CHMP) of theEuropean Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a conditional marketing authorization for the medicinal product Lytgobi, intended for the second-line treatment of locally advanced or metastatic cholangiocarcinoma characterized by fusion or rearrangements of fibroblast growth factor receptor (FGFR) 2.[12] The applicant for this medicinal product is Taiho Pharma Netherlands B.V.[12] Futibatinib was approved for medical use in the European Union in July 2023.[4]
Futibatinib is theinternational nonproprietary name (INN).[13]
This article incorporates text from this source, which is in thepublic domain. | Thispharmacology-related article is astub. You can help Wikipedia byexpanding it. |
